Cargando…
CD19/CD22 chimeric antigen receptor (CAR) T-cell cocktail therapy following autologous transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma on (18)F-FDG PET/CT: a case description
Autores principales: | Zhou, Yeye, Sang, Shibiao, Zhang, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347323/ https://www.ncbi.nlm.nih.gov/pubmed/37456277 http://dx.doi.org/10.21037/qims-22-1209 |
Ejemplares similares
-
Prognostic Value of Radiomic Features of (18)F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells
por: Zhou, Yeye, et al.
Publicado: (2022) -
Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma
por: Huang, Lefu, et al.
Publicado: (2022) -
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
por: Tambaro, Francesco Paolo, et al.
Publicado: (2021) -
Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023) -
Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
por: Wei, Jia, et al.
Publicado: (2020)